Synthesis and characterization of heptacoordinated tin(IV) complexes. X-ray crystal structure of [nBu2Sn(dappt)]·(Me 2CO)0.5 [H2dappt = 2,6-diacetylpyridine bis(4-phenylthiosemicarbazone)]

As reações do ligante 2,6-diacetilpiridina bis(4-feniltiossemicarbazona), H2dappt, com R4-mSnXm (m = 2, 3; R = Me, nBu, Ph e X = Cl) resultaram na formação de quatro novos complexos organoestânicos heptacoordenados, os quais foram caracterizados por análise elementar e pelas espectroscopias no IV e Mössbauer. O derivado n-butila, [nBu2Sn(dappt)]·(Me 2CO)0.5, foi também analisado por um estudo de difração de raios X em um monocristal. O complexo cristalizou-se no sistema monoclínico e grupo espacial C2/c, com a = 36,164(14), b = 9,7050(15), c = 26,194(11) Å, beta = 132,00(2)º, Z = 8. A determinação da estrutura revelou um complexo neutro de Sn(IV), numa geometria bipiramidal pentagonal (BPP), com o plano equatoral definido pelos átomos doadores SNNNS do ligante e dois grupos n-bultila nas posições axiais. Também é discutida uma correlação entre os dados de Mössbauer e de difração de raios X, baseada no modelo da carga-pontual.The reactions of the 2,6-diacetylpyridine bis(4-phenylthiosemicarbazone) ligand, H2dappt, with R4-mSnXm (m = 2, 3; R = Me, nBu, Ph and X = Cl) led to the formation of four new heptacoordinated organotin(IV) complexes, which were characterized by microanalyses and by IR and Mössbauer spectroscopies. The n-butyl derivative [nBu2Sn(dappt)]·(Me 2CO)0.5 was also analyzed by a single crystal X-ray diffraction study. It crystallized in the monoclinic system with a space group C2/c, with a = 36.164(14), b = 9.7050(15), c = 26.194(11) Å, beta = 132.00(2)º, Z = 8. The structure determination revealed a neutral complex of Sn(IV) in a distorted pentagonal bipyramidal (PBP) geometry, with the equatorial plane defined by the SNNNS donor system of the ligand and with the two n-butyl groups in the axial positions. Also, a correlation between Mössbauer and X-ray data based on the point-charge model is discussed.The reactions of the 2,6-diacetylpyridine bis(4-phenylthiosemicarbazone) ligand, H2dappt, with R4-mSnXm (m = 2, 3; R = Me, nBu, Ph and X = Cl) led to the formation of four new heptacoordinated organotin(IV) complexes, which were characterized by microanalyses and by IR and Mössbauer spectroscopies. The n-butyl derivative [nBu2Sn(dappt)]·(Me 2CO)0.5 was also analyzed by a single crystal X-ray diffraction study. It crystallized in the monoclinic system with a space group C2/c, with a = 36.164(14), b = 9.7050(15), c = 26.194(11) Å, beta = 132.00(2)º, Z = 8. The structure determination revealed a neutral complex of Sn(IV) in a distorted pentagonal bipyramidal (PBP) geometry, with the equatorial plane defined by the SNNNS donor system of the ligand and with the two n-butyl groups in the axial positions. Also, a correlation between Mössbauer and X-ray data based on the point-charge model is discussed

Novel zwitterionic oxorhenium(V) complexes: synthesis, characterization and crystal structure of [ReOX2(Hdhp)(PPh3)] (X = Cl, Br; H2dhp = 2,3-dihydroxypyridine)

Dois novos complexos zwitteriônicos de oxorrênio(V), [ReOCl2(Hdhp)(PPh3)] (1) e [ReOBr2(Hdhp)(PPh3)] (2) (H2dhp = 2,3-dihidroxipiridina), foram sintetizados e caracterizados por espectroscopia de absorção no infravermelho, ressonância magnética nuclear de ¹H e 31P, análise elementar e determinação da estrutura cristalina e molecular por difração de raios X em monocristais. Os complexos apresentam geometria de coordenação octaédrica bastante distorcida, com os dois ligantes haletos arranjados em posições cis equatoriais, o ligante trifenilfosfina em posição trans a um dos haletos e o ligante Hdhp- coordenado de forma bidentada através de seus átomos de oxigênio, sendo um em posição trans ao ligante oxo e o outro em posição trans com relação ao outro haleto. Este ligante tem seu átomo de nitrogênio protonado. Os compostos 1 e 2 apresentam empacotamento cristalino bastante diferente, influenciado em ambos os casos por ligações de hidrogênio intermoleculares dos tipos N-H...X (X = Cl, Br) e N-H...O.Two novel zwitterionic oxorhenium(V) complexes, [ReOCl2(Hdhp)(PPh3)] (1) and [ReOBr2(Hdhp)(PPh3)] (2) (H2dhp = 2,3-dihydroxypyridine), were synthesized and characterized by infrared spectroscopy, ¹H and 31P nuclear magnetic resonance, elemental analysis and crystal and molecular structure determination by X-ray diffraction on single crystals. Both complexes show distorted octahedral coordination geometry, with the halide ligands arranged in equatorial cis positions, the triphenylphosphine ligand in a trans position to one of the halides and the Hdhp- ligand coordinated in a bidentate form through its oxygen atoms, one in trans position to the oxo-ligand and the other in trans position to the second halide. The nitrogen atom of this ligand is protonated. Compounds 1 and 2 show quite different crystal packing, both influenced by hydrogen bonds of the types N-H...X (X = Cl, Br) and N-H...O

Palladium(II) complexes with thiosemicarbazones: syntheses, characterization and cytotoxicity against breast cancer cells and anti-mycobacterium tuberculosis activity

Three PdII complexes were prepared from N(4)-substituted thiosemicarbazones: [Pd(aptsc)(PPh3)](NO3)•H2O, 1, [Pd(apmtsc)(PPh3)](NO3), 2, and [Pd(apptsc)(PPh3)](NO3)•H2O, 3, where PPh3 = triphenylphosphine; Haptsc = 2-acetylpyridine-thiosemicarbazone; Hapmtsc = 2-acetylpyridine-N(4)-methyl-thiosemicarbazone and Happtsc = 2-acetylpyridine-N(4)-phenyl-thiosemicarbazone. All complexes were characterized by elemental analysis, IR, UV-Vis, 1H and 31P{1H} NMR spectroscopies, and had their crystalline structures determined by X-ray diffractometry from single crystals. The monoanionic thiosemicarbazonate ligands act in a tridentate mode, binding to the metal through the pyridine nitrogen, the azomethine nitrogen and the sulfur atoms. The cytotoxic activity against the breast cancer cell line MDA-MB231 and the anti-Mycobacterium tuberculosis H37Rv ATCC 27294 activity were evaluated for the compounds. All PdII complexes were highly active against the studied cell line, presenting similar values of IC50, around 5 µmol L-1, while the clinically applied antitumor agent cisplatin was inactive. The compounds show remarkable anti-M. tuberculosis activities, presenting MIC values comparable or better than some commercial anti-M tuberculosis drugs.FAPESPCAPESCNPqFINE

Palladium(II) complexes with thiosemicarbazones: syntheses, characterization and cytotoxicity against breast cancer cells and Anti-Mycobacterium tuberculosis activity

Três complexos de PdII com tiossemicarbazonas N(4)-substituídas foram preparados: [Pd(aptsc)(PPh3)](NO3) H2O, 1, [Pd(apmtsc)(PPh3)](NO3), 2, e [Pd(apptsc)(PPh3)](NO3) H2O, 3, sendo PPh3 = trifenilfosfina; Haptsc = 2-acetilpyridina-tiossemicarbazona; Hapmtsc = 2-acetilpiridina-N(4)-metil-tiossemicarbazona e Happtsc = 2-acetilpiridina-N(4)-fenil-tiossemicarbazona. Os complexos foram caracterizados por análise elementar, IR, UV-Vis, ¹H e 31P{¹H} NMR e tiveram suas estruturas cristalinas determinadas por difratometria de raios X em monocristal. Os ligantes tiossemicarbazonatos monoaniônicos atuam de modo tridentado, ligando-se ao metal pelos átomos de nitrogênio piridínico, nitrogênio azometínico e enxofre. A atividade citotóxica frente à linhagem de células tumorais MDA-MB231 (tumor de mama) e a atividade anti-Mycobacterium tuberculosis H37Rv ATCC 27294 dos compostos foram investigadas. Os complexos de PdII mostraram-se altamente ativos contra as células tumorais, com valores de IC50 em torno de 5 µmol L-1, enquanto o agente antitumoral em uso clínico cisplatina mostrou-se inativo. Os compostos apresentaram atividade anti-M. tuberculosis significante, com valores de CIM comparáveis ou melhores que aqueles referentes a alguns fármacos usados clinicamente contra tuberculose.Three PdII complexes were prepared from N(4)-substituted thiosemicarbazones: [Pd(aptsc)(PPh3)](NO3) H2O, 1, [Pd(apmtsc)(PPh3)](NO3), 2, and [Pd(apptsc)(PPh3)](NO3) H2O, 3, where PPh3 = triphenylphosphine; Haptsc = 2-acetylpyridine-thiosemicarbazone; Hapmtsc = 2-acetylpyridine-N(4)-methyl-thiosemicarbazone and Happtsc = 2-acetylpyridine-N(4)-phenyl-thiosemicarbazone. All complexes were characterized by elemental analysis, IR, UV-Vis, ¹H and 31P{¹H} NMR spectroscopies, and had their crystalline structures determined by X-ray diffractometry from single crystals. The monoanionic thiosemicarbazonate ligands act in a tridentate mode, binding to the metal through the pyridine nitrogen, the azomethine nitrogen and the sulfur atoms. The cytotoxic activity against the breast cancer cell line MDA-MB231 and the anti-Mycobacterium tuberculosis H37Rv ATCC 27294 activity were evaluated for the compounds. All PdII complexes were highly active against the studied cell line, presenting similar values of IC50, around 5 µmol L-1, while the clinically applied antitumor agent cisplatin was inactive. The compounds show remarkable anti-M. tuberculosis activities, presenting MIC values comparable or better than some commercial anti-M tuberculosis drugs

A dimeric oxidovanadium(V) complex derived from a hydrazonate ligand with an unusual asymmetrically bridged μ-(oxido)μ-(H2O){oxidovanadium(V)}2 core

The binuclear oxidovanadium(V) complex [{VO(L)}2(μ-O)(μ-H2O)]∙2CH3CN (1), where L2– is the dianion of the Schiff base 2-salicylaldehyde-2-hydroxybenzoylhydrazone, were prepared and characterized by elemental analysis, FTIR, 1H, 13C and 51V NMR. Furthermore, the crystal structure of the compound 1 was determined by single crystal X-ray diffractometry revealing a distorted octahedral O5N-coordination geometry around the V(V) acceptor centers. The vanadium ions are connected by the μ-O2– and the μ-H2O asymmetric bridges located in the edge between the two octahedrons which keeps a distance of 3.194 Å between the two vanadium centers. Crystal data for C32H28N6O10V2 (M =758.48 g/mol): orthorhombic, space group P212121 (no. 19), a = 12.9655(8) Å, b = 14.1902(9) Å, c = 18.4379(10) Å, V = 3392.3(4) Å3, Z = 4, T = 293(2) K, μ(MoKα) = 0.616 mm-1, Dcalc = 1.485 g/cm3, 18803 reflections measured (3.622° ≤ 2Θ ≤ 56.704°), 8263 unique (Rint = 0.0473, Rsigma = 0.1020) which were used in all calculations. The final R1 was 0.0509 (I > 2σ(I)) and wR2 was 0.1531 (all data). The (VO)2(μ-O)(μ-H2O) core in compound 1 represents a rare case and few examples of similar type have been structurally characterized

Tricarbonyltechnetium(I) and -rhenium(I) complexes with N '-thiocarbamoylpicolylbenzamidines

N,N-Dialkylamino(thiocarbonyl)-N'-picolylbenzamidines react with (NEt4)(2)[M(CO)(3)X-3] (M = Re, X = Br: M = Tc, X = Cl) under formation of neutral [M(CO)(3)L] complexes in high yields. The monoanionic NNS ligands bind in a facial coordination mode and can readily be modified at the (CS)(NRR2)-R-1 moiety. The complexes [Tc-99(CO)(3)(L-PyMor)] and]Re(CO)(3)(L)] (L = L-PyMor, L-PyEt) were characterized by X-ray diffraction. Reactions of [Tc-99m(CO)(3)(H2O)(3)](+) with the N'-thiocarbamoylpicolylbenzamidines give the corresponding Tc-99m complexes. The ester group in HLPyCOOEr allows linkage between biomolecules and the metal core. (C) 2012 Elsevier Ltd. All rights reserved

Ruthenium(II) complexes with 2-(diphenylphosphinomethyl)aniline

2-(Diphenylphosphinomethyl)aniline. H2L1, reacts with [RuCl2(PPh3)(3)] to yield the monomeric complexes [RuCl2(H2L1)(PPh3)(CH3CN)], [RuCl2(H2L1)(2)]and the chloro-bridged dimer [(H2L1)(PPh3)Ru(mu-Cl)(2)Ru(PPh3) (H2L1)] depending on the conditions applied. Exclusively the monochelate [RuCl2 (H2L1)(dmso)(2)] is formed during reactions of H2L1 with [RuCl2(dmso)(4)]. H2L1 acts as a neutral, bidentate ligand in all complexes. The products are studied spectroscopically and by X-ray diffraction. (C) 2012 Elsevier Ltd. All rights reserved.DAAD (Germany)DAAD (Germany)CAPES (Brazil)CAPES (Brazil

Neutral Gold Complexes with Tridentate SNS Thiosemicarbazide Ligands

Na[AuCl4].2H(2)O reacts with tridentate thiosemicarbazide ligands, H(2)L1, derived from N-[N',N'-dialkylamino(thiocarbonyl)]benzimidoyl chloride and thiosemicarbazides under formation of air-stable, green [AuCl(L1)] complexes. The organic ligands coordinate in a planar SNS coordination mode. Small amounts of gold(I) complexes of the composition [AuCl(L3)] are formed as side-products, where L3 is an S-bonded 5-diethylamino-3-phenyl-1-thiocarbamoyl-1,2,4-triazole. The formation of the triazole L3 can be explained by the oxidation of H(2)L1 to an intermediate thiatriazine L2 by Au3+, followed by a desulfurization reaction with ring contraction. The chloro ligands in the [AuCl(L1)] complexes can readily be replaced by other monoanionic ligands such as SCN- or CN- giving [Au(SCN)(L1)] or [Au(CN)(L1)] complexes. The complexes described in this paper represent the first examples of fully characterized neutral Gold(III) thiosemicarbazone complexes. All the [AuCl(L1)] compounds present a remarkable cell growth inhibition against human MCF-7 breast cancer cells. However, systematic variation of the alkyl groups in the N(4)-position of the thiosemicarbazone building blocks as well as the replacement of the chloride by thiocyanate ligands do not considerably influence the biological activity. On the other hand, the reduction of Au-III to Au-I leads to a considerable decrease of the cytotoxicity.DAADDAADCAPESCAPESCNPqCNPqFAPESPFAPES

Latent Tuberculosis: A Promising New Compound to Treat Non-Replicating and Intramacrophagic Mycobacteria

As a biologic reservoir of Mycobacterium tuberculosis (M. tb), one-quarter of the world population is infected with the well-known latent tuberculosis (LTBI). About 5–10% of LTBI patients will progress to active disease in the first years after primary infection and, despite using the recommended treatment, 20% can still reactivate the infection. A new LTBI treatment could minimize adverse effects and antibiotic resistance that can occur when the same drug is used to treat the latent and active disease. New hydrazones were evaluated, and they showed great inhibitory activity against intramacrophagic and non-replicating M. tb, commonly found at this stage of infection, in addition to bactericidal and narrow-spectrum activity. When tested against eukaryotic cells, the hydrazones showed great safety at different exposure times. In vitro, these compounds performed better than isoniazid and could be considered new candidates for LTBI treatment, which may promote greater engagement in its prescription and adherence

Nitroisatin dithiocarbazate: Synthesis, structural characterization, DFT, and docking studies

The reaction between 5-nitroisatin with S-benzyl dithiocarbazate affords a new isatindithio carbazate so-called NO2Isadtc (Benzyl 2-(5-nitro-2-oxoindolin-3-ylidene)hydrazinecarbodi thioate) which was characterized by means of 1H NMR, FT-IR, UV-visible and single crystal X-ray diffraction - Crystal data for C16H12N4O3S2 (M =372.42 g/mol): triclinic space group P-1, (n°. 02), a = 6.640 Å, b = 8.256 Å, c = 15.908 Å, V = 849.6 Å3, Z = 2, T = 293 K, μ(MoKα) = 0.337 mm-1, Dcalc = 1.456 g/cm3, 27515 reflections measured (2.499° ≤ 2Θ ≤ 26.524°), 3518 unique (Rint = 0.0533, Rsigma =0.0222) which were used in all calculations. The final R1 was 0.0367 (I > 2σ(I)) and wR2 was 0.1045 (all data). Computational methods were applied to NO2Isadtc and its nonsubstituted parent compound Isadtc for structure optimization, electronic distribution, and infrared calculations using B3LYP functional with 6-31G(d,p) basis set in ethanol as a polarizable continuum model. Furthermore, docking studies using human thioredoxin reductase 1 (TrxR) as enzyme target also were performed using NO2Isadtc and the optimized structure of Isadtc. The results demonstrated that both NO2Isadtc and Isadtc may act as inhibitors of TrxR, having different interactions detected, highlighting the contact between the NO2 group and the S111 at the helix which is found for NO2Isadtc